Literature DB >> 24362370

Screening of NLGN3 and NLGN4X genes in Thai children with autism spectrum disorder.

Anna Mikhailov1, Alanna Fennell, Oradawan Plong-on, Thanya Sripo, Tippawan Hansakunachai, Rawiwan Roongpraiwan, Tasnawat Sombuntham, Nichara Ruangdaraganon, John B Vincent, Pornprot Limprasert.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24362370     DOI: 10.1097/YPG.0000000000000019

Source DB:  PubMed          Journal:  Psychiatr Genet        ISSN: 0955-8829            Impact factor:   2.458


× No keyword cloud information.
  4 in total

1.  Imbalance of flight-freeze responses and their cellular correlates in the Nlgn3-/y rat model of autism.

Authors:  Natasha J Anstey; Vijayakumar Kapgal; Emma R Wood; Oliver Hardt; Peter C Kind; Shashank Tiwari; Thomas C Watson; Anna K H Toft; Owen R Dando; Felicity H Inkpen; Paul S Baxter; Zrinko Kozić; Adam D Jackson; Xin He; Mohammad Sarfaraz Nawaz; Aiman Kayenaat; Aditi Bhattacharya; David J A Wyllie; Sumantra Chattarji
Journal:  Mol Autism       Date:  2022-07-18       Impact factor: 6.476

2.  Mutation screening of the neurexin 1 gene in thai patients with intellectual disability and autism spectrum disorder.

Authors:  Supaporn Yangngam; Oradawan Plong-On; Thanya Sripo; Rawiwan Roongpraiwan; Tippawan Hansakunachai; Juthamas Wirojanan; Tasnawat Sombuntham; Nichara Ruangdaraganon; Pornprot Limprasert
Journal:  Genet Test Mol Biomarkers       Date:  2014-05-15

3.  Analysis of the SNP rs3747333 and rs3747334 in NLGN4X gene in autism spectrum disorder: a meta-analysis.

Authors:  Hongli Sun; Ying Yang; Liyu Zhang; Haibin Wu; Huifang Zhang; Hui Li
Journal:  Ann Gen Psychiatry       Date:  2019-05-21       Impact factor: 3.455

4.  X-exome sequencing of 405 unresolved families identifies seven novel intellectual disability genes.

Authors:  H Hu; S A Haas; J Chelly; H Van Esch; M Raynaud; A P M de Brouwer; S Weinert; G Froyen; S G M Frints; F Laumonnier; T Zemojtel; M I Love; H Richard; A-K Emde; M Bienek; C Jensen; M Hambrock; U Fischer; C Langnick; M Feldkamp; W Wissink-Lindhout; N Lebrun; L Castelnau; J Rucci; R Montjean; O Dorseuil; P Billuart; T Stuhlmann; M Shaw; M A Corbett; A Gardner; S Willis-Owen; C Tan; K L Friend; S Belet; K E P van Roozendaal; M Jimenez-Pocquet; M-P Moizard; N Ronce; R Sun; S O'Keeffe; R Chenna; A van Bömmel; J Göke; A Hackett; M Field; L Christie; J Boyle; E Haan; J Nelson; G Turner; G Baynam; G Gillessen-Kaesbach; U Müller; D Steinberger; B Budny; M Badura-Stronka; A Latos-Bieleńska; L B Ousager; P Wieacker; G Rodríguez Criado; M-L Bondeson; G Annerén; A Dufke; M Cohen; L Van Maldergem; C Vincent-Delorme; B Echenne; B Simon-Bouy; T Kleefstra; M Willemsen; J-P Fryns; K Devriendt; R Ullmann; M Vingron; K Wrogemann; T F Wienker; A Tzschach; H van Bokhoven; J Gecz; T J Jentsch; W Chen; H-H Ropers; V M Kalscheuer
Journal:  Mol Psychiatry       Date:  2015-02-03       Impact factor: 15.992

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.